The AAV gene therapy field is scaling beyond rare genetic diseases to address larger patient populations including cardiovascular and neurological conditions like Alzheimer’s and Parkinson’s. Scaling AAV production from research bench to commercial manufacturing is complex, requiring extensive process optimization to ensure consistent batch quality and yield. Eva Fong from MilliporeSigma highlights how partnering with experienced CDMOs using optimized platform solutions can mitigate risks, increase viral vector quality and yield, and reduce costs. This approach supports efficient clinical and commercial advancement amid macroeconomic pressures.